ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by State Street Corp

State Street Corp lifted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 61.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,004,993 shares of the biotechnology company's stock after purchasing an additional 4,945,063 shares during the period. State Street Corp owned about 5.58% of ADMA Biologics worth $259,970,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of ADMA. Bank of Montreal Can purchased a new position in shares of ADMA Biologics in the second quarter valued at approximately $17,886,000. D. E. Shaw & Co. Inc. raised its position in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock valued at $76,298,000 after buying an additional 1,442,799 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after buying an additional 1,059,394 shares in the last quarter. First Turn Management LLC acquired a new position in ADMA Biologics during the third quarter worth about $13,293,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in ADMA Biologics during the 2nd quarter valued at about $6,468,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. Finally, HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th.

Insiders Place Their Bets

In other news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.70% of the stock is owned by company insiders.

ADMA Biologics Trading Up 2.2 %

NASDAQ:ADMA traded up $0.42 during trading hours on Wednesday, reaching $19.63. 1,595,768 shares of the stock were exchanged, compared to its average volume of 3,594,533. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The business has a 50-day moving average of $19.07 and a two-hundred day moving average of $15.90. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of 68.61 and a beta of 0.70. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the business posted $0.01 EPS. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.